Summit Therapeutics Inc.
SMMT Nasdaq
SEC CIK 1599298
Follow Summit Therapeutics
Weekly email: filings, results
Net income
−$208.4M
+10.1% vs same quarter last year
EPS, diluted
−$0.26
+16.1% vs same quarter last year
Operating cash flow
−$159.8M
−71.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$1.1B |
| FY24 | $0 | −$221.3M |
| FY23 | $0 | −$614.9M |
| FY22 | $705K | −$78.8M |
| FY21 | $1.8M | −$88.6M |
| FY20 | $860K | −$52.7M |
| FY19 | $57.1M | $10.9M |
| FY18 | $16.1M | −$26.4M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | −10225.4% | −11174.8% |
| FY21 | −4764.3% | −4897.8% |
| FY20 | −6185.2% | −6127.6% |
| FY19 | 9.4% | 19% |
| FY18 | −176.1% | −163.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$323.6M |
| FY24 | −$142.2M |
| FY23 | −$76.9M |
| FY22 | −$42.2M |
| FY21 | −$72.9M |
| FY20 | −$48.5M |
| FY19 | −$35.3M |
| FY18 | −$22.2M |
- Summit Therapeutics
- Healthcare median
Show the numbers
| Year | Summit Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −11174.8% | −80.4% |
| FY21 | −4897.8% | −71.8% |
| FY20 | −6127.6% | −62.2% |
| FY19 | 19% | −46.2% |
| FY18 | −163.6% | −49.6% |